An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for March 1, 2022, at 4:30 p.m. Eastern Time
Senseonics Holdings, Inc. (AMEX: SENS) will release its fourth quarter and full year 2021 financial results on March 1, 2022, after market close. A conference call will follow at 4:30 p.m. ET to discuss performance details. Investors can access the call by dialing specific numbers or through a webcast on the company’s website. Senseonics focuses on developing long-term, implantable continuous glucose monitoring (CGM) systems, with products like Eversense® and Eversense® E3 designed to enhance diabetes management.
Positive
None.
Negative
None.
GERMANTOWN, Md.--(BUSINESS WIRE)--
Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2021 financial results after market close on Tuesday, March 1, 2022.
Management will hold a conference call to review the Company’s fourth quarter and full year 2021 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-888-317-6003 (US/Canada) or 1-412-317-6061 (International), passcode 2775821, approximately ten to five minutes prior to start time.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems, Eversense®, Eversense® XL and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
Senseonics Investor Contact
Lynn Lewis or Philip Taylor Investor Relations
415-937-5406
investors@senseonics.com
Source: Senseonics Holdings, Inc.
FAQ
When will Senseonics release its financial results for Q4 2021?
Senseonics will release its Q4 and full year 2021 financial results on March 1, 2022.
What time is the Senseonics conference call scheduled?
The conference call is scheduled for 4:30 p.m. Eastern Time on March 1, 2022.
How can I listen to the Senseonics conference call?
You can listen to the conference call by dialing 1-888-317-6003 (US/Canada) or 1-412-317-6061 (International), or via webcast on the Senseonics website.
What products does Senseonics offer for diabetes management?
Senseonics offers long-term implantable continuous glucose monitoring systems, including Eversense®, Eversense® XL, and Eversense® E3.
